T-cell lymphoma

   

 

T-Cell Lymphoma

There are many types of T-cell lymphoma, just as there are many B-cell types of lymphoma. Although this page appears grouped with the other aggressive forms of NHL there are also indolent T-cell types so if you don't see your type here, look in the indolent lymphoma section.

 

There is still no consensus about whether T-cell lymphomas respond as well to treatment as their corresponding B-cell types. Most experts will agree that they remain a challenge to treat.

 

Here are some excellent articles that discuss T-cell lymphomas in-depth.

 

This first link is to a webcast from Jasmine Zain, MD Columbia University Medical Center, New York.(Approx 45 minutes long)

How I treat T-Cell lymphomas

 

Next we have The CancerNetworks latest series about T-cell lymphomas.

Peripheral T-cell lymphomas: Their time has come

 

Next we have the Grand Rounds in Hematology newsletter from Bloodline.

Click here to read the newsletter

 

The Cancer network's T-cell lymphoma series.

Primary Cutaneous and Systemic Anaplastic Large Cell Lymphoma

 

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

 

Topics covered in the above newsletter include:

  • Introduction
  • Update on the Pathophysiology of T-cell Lymphomas
  • Therapeutic options for patients with Peripheral T-cell lymphoma
  • Clinical Vignettes in Cutaneous T-Cell Lymphoma: Practical Applications for Emerging Data on Mycosis Fungoides/Sézary Syndrome
  • What's new in Gastric MALT lymphoma
  • Primary  Central Nervous System Lymphoma.

Below is an article from the ASH education series that reviews the biology, prognosis and treatment options for T-cell lymphomas, with an emphasis on peripheral T-cell types.

ASH education review of T-cell lymphomas

 

Another important new treatment is Pralatrexate. The recently published PROPEL clinical trial showed a 27% response rate in patients with relapsed or refractory Peripheral T-cell lymphoma. Click the link below to read the press release from Allos Therapeutics.

Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma